Roquefort Therapeutics (LSE:ROQ) Accounts Payable & Accrued Expense : £0.15 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Accounts Payable & Accrued Expense?

Roquefort Therapeutics's quarterly accounts payable & accrued expense increased from Dec. 2022 (£0.07 Mil) to Jun. 2023 (£0.28 Mil) but then declined from Jun. 2023 (£0.28 Mil) to Dec. 2023 (£0.15 Mil).

Roquefort Therapeutics's annual accounts payable & accrued expense increased from Dec. 2021 (£0.04 Mil) to Dec. 2022 (£0.07 Mil) and increased from Dec. 2022 (£0.07 Mil) to Dec. 2023 (£0.15 Mil).

Roquefort Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Roquefort Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Accounts Payable & Accrued Expense Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

0.04

0.07

0.15

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	0.01	1.05	0.07	0.28	0.15

Roquefort Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines